Smallpox vaccines : Past, present, and future : VaccinesPARRINO, Janie; GRAHAM, Barney S.Journal of allergy and clinical immunology. 2006, Vol 118, Num 6, pp 1320-1326, issn 0091-6749, 7 p.Article

Viral and Host Factors in Human Respiratory Syncytial Virus PathogenesisCOLLINS, Peter L; GRAHAM, Barney S.Journal of virology. 2008, Vol 82, Num 5, pp 2040-2055, issn 0022-538X, 16 p.Article

Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding virusesBUDGE, Philip J; GRAHAM, Barney S.Journal of antimicrobial chemotherapy (Print). 2004, Vol 54, Num 2, pp 299-302, issn 0305-7453, 4 p.Article

Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimersBUDGE, Philip J; LEBOWITZ, Jacob; GRAHAM, Barney S et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 11, pp 3470-3477, issn 0066-4804, 8 p.Article

Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitroGOWER, Tara L; GRAHAM, Barney S.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 4, pp 1231-1237, issn 0066-4804Article

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. CommentaryGRAHAM, Barney S; MASCOLA, John R.The Journal of infectious diseases. 2005, Vol 191, Num 5, pp 654-665, issn 0022-1899, 15 p.Article

Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2JOHNSON, Teresa R; MCLELLAN, Jason S; GRAHAM, Barney S et al.Journal of virology. 2012, Vol 86, Num 3, pp 1339-1347, issn 0022-538X, 9 p.Article

Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentGRAHAM, Barney S.Immunological reviews. 2011, Vol 239, pp 149-166, issn 0105-2896, 18 p.Article

RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV GBUDGE, Philip J; YEQIANG LI; BEELER, Judy A et al.Journal of virology. 2004, Vol 78, Num 10, pp 5015-5022, issn 0022-538X, 8 p.Article

Modified vaccinia ankara: Potential as an alternative smallpox vaccineMCCURDY, Lewis H; LARKIN, Brenda D; MARTIN, Julie E et al.Clinical infectious diseases. 2004, Vol 38, Num 12, pp 1749-1753, issn 1058-4838, 5 p.Article

Characterization of Respiratory Syncytial Virus M-and M2-Specific CD4 T Cells in a Murine ModelJIE LIU; RUCKWARDT, Tracy J; MAN CHEN et al.Journal of virology. 2009, Vol 83, Num 10, pp 4934-4941, issn 0022-538X, 8 p.Article

Regulatory T Cells Promote Early Influx of CD8⁺ T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance DisparitiesRUCKWARDT, Tracy J; BONAPARTE, Kathryn L; NASON, Martha C et al.Journal of virology. 2009, Vol 83, Num 7, pp 3019-3028, issn 0022-538X, 10 p.Article

Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infectionJOHNSON, Teresa R; GRAHAM, Barney S.The Pediatric infectious disease journal. 2004, Vol 23, Num 1, pp S46-S57, issn 0891-3668, SUPConference Paper

Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infectionFISCHER, Julie E; JOHNSON, Joyce E; JOHNSON, Teresa R et al.The Journal of infectious diseases. 2000, Vol 182, Num 4, pp 1029-1038, issn 0022-1899Article

Vβ14⁺ T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVJOHNSON, Teresa R; VARGA, Steven M; BRACIALE, Thomas J et al.Journal of virology. 2004, Vol 78, Num 16, pp 8753-8760, issn 0022-538X, 8 p.Article

Immune-mediated disease pathogenesis in respiratory syncytial virus infectionGRAHAM, Barney S; JOHNSON, Teresa R; PEEBLES, R. Stokes et al.Immunopharmacology (New York). 2000, Vol 48, Num 3, pp 237-247, issn 0162-3109Conference Paper

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing EpitopesMCLELLAN, Jason S; YONGPING YANG; GRAHAM, Barney S et al.Journal of virology. 2011, Vol 85, Num 15, pp 7788-7796, issn 0022-538X, 9 p.Article

Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4MCCURDY, Lewis H; RUTIGLIANO, John A; JOHNSON, Teresa R et al.Journal of virology. 2004, Vol 78, Num 22, pp 12471-12479, issn 0022-538X, 9 p.Article

TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severityJOHNSON, Teresa R; RAO, Srinivas; SEDER, Robert A et al.Vaccine. 2009, Vol 27, Num 23, pp 3045-3052, issn 0264-410X, 8 p.Article

Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSVJOHNSON, Teresa R; TENG, Michael N; COLLINS, Peter L et al.Journal of virology. 2004, Vol 78, Num 11, pp 6024-6032, issn 0022-538X, 9 p.Article

Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite VaccineSEDER, Robert A; CHANG, Lee-Jah; RICHMAN, Adam et al.Science (Washington, D.C.). 2013, Vol 341, Num 6152, pp 1359-1365, issn 0036-8075, 7 p.Article

IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouseWEISONG ZHOU; HASHIMOTO, Koichi; O'NEAL, Jamye F et al.Microbes and infection. 2006, Vol 8, Num 14-15, pp 2880-2889, issn 1286-4579, 10 p.Article

Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virusWRIGHT, Peter F; GRUBER, William C; PETERS, Melissa et al.The Journal of infectious diseases. 2002, Vol 185, Num 8, pp 1011-1018, issn 0022-1899Article

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trialsLEDGERWOOD, Julie E; WEI, Chih-Jen; BAILER, Robert et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 12, pp 916-924, issn 1473-3099, 9 p.Article

Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human TrialsKOUP, Richard A; LAMOREAUX, Laurie; ZARKOWSKY, David et al.Journal of virology. 2009, Vol 83, Num 12, pp 6318-6322, issn 0022-538X, 5 p.Article